Background: Korean Red Ginseng (KRG) is a traditional herbal medicine made by steaming and drying fresh ginseng. It strengthens the endocrine and immune systems to ameliorate various inflammatory responses. The cyclooxygenase-2 (COX-2)/prostaglandin E2 pathway has important implications for inflammation responses and tumorigenesis. Peroxisome proliferator-activated receptor gamma (PPARg) is a transcription factor that regulates not only adipogenesis and lipid homeostasis, but also angiogenesis and inflammatory responses. Methods: The effects of the KRG on inhibition of hypoxia-induced COX-2 via PPARg in A549 cells were determined by luciferase assay, Western blot, and/or quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The antimigration and invasive effects of KRG were evaluated on A549 cells using migration and matrigel invasion assays. Results and conclusion: We previously reported that hypoxia-induced COX-2 protein and mRNA levels were suppressed by KRG. This study examines the possibility of PPARg as a cellular target of KRG for the suppression of hypoxia-induced COX-2. PPARg protein levels and PPARg-responsive element (PPRE)-driven reporter activities were increased by KRG. Reduction of hypoxia-induced COX-2 by KRG was abolished by the PPARg inhibitor GW9662. In addition, the inhibition of PPARg abolished the effect of KRG on hypoxia-induced cell migration and invasion. Discussion: Our results show that KRG inhibition of hypoxia-induced COX-2 expression and cell invasion is dependent on PPARg activation, supporting the therapeutic potential for suppression of inflammation under hypoxia. Further studies are required to demonstrate whether KRG activates directly PPARg and to identify the constituents responsible for this activity.
Introduction
Ginseng is a popular herbal medicine that has been used for over 2,000 y in Oriental countries. Its use is not confined to Asia but has expanded to Western countries as one of the top 10 best-selling herbs [1] . This popularity and its worldwide consumption indirectly demonstrate its efficacy, and accumulating scientific evidence shows that ginseng has a wide range of pharmacological activities in the cardiovascular, endocrine, immune, and central nervous systems [2] . It is especially well established that ginseng ameliorates inflammatory responses [3e5] . Data have shown that ginsenosides are pharmacological compounds with antiinflammatory and anticarcinogenic effects both in vivo and in vitro [6, 7] .
Red ginseng is made by steaming and drying fresh ginseng. The pharmacological efficacy of Korean ginseng is known to be enhanced by these special processes, mostly due to changes in the characteristics of the constituent ginsenosides [8, 9] . During the steaming process, seven ginsenosides (Rg1, Re, Rb1, Rc, Rb2, Rb3, and Rd) decreased, while five ginsenosides (Rh1, Rg2, 20R-Rg2, Rg3, and Rh2) increased [10] .
Hypoxia is a state of reduced overall tissue oxygen availability and a hallmark of solid tumors that leads to cell invasion and metastasis [11] . Cyclooxygenase-2 (COX-2) is induced by various stimuli such as lipopolysaccharide (LPS), cytokines, hypertonicity, and hypoxia [12e15] . COX-2 increases the metastatic potential of cancer cells, and silencing COX-2 inhibits metastasis and delays tumor onset in poorly differentiated metastatic cancers [16, 17] . Mammary epithelial cells express peroxisome proliferatoractivated receptor gamma (PPARg), and its signaling is critical during breast tumorigenesis and correlated with COX-2 expression [18] . These observations indicate the importance of COX-2 inhibition in preventing hypoxia-induced cell invasion.
PPARg, a member of a nuclear receptor superfamily, heterodimerizes with the retinoid X receptor and activates transcription by binding to the PPAR response elements of its target genes [19] . Endogenous ligands for PPARg include fatty acids and prostanoids. PPARg regulates adipogenesis by differentiating adipocytes, lipid metabolism, inflammation, and angiogenesis [20] . PPARg regulates COX-2 gene expression through PPAR response elements within the promoter of COX-2 [21, 22] . However, depending on the cell type, PPARg can both activate and inhibit COX-2 through PPARg-dependent and -independent mechanisms [23e25]. Continuous research is required to understand these complex phenomena. PPARg-activating natural products and plant extracts have been extensively sought after and studied because of their great potential for use in the treatment of a variety of metabolic syndromes [26, 27] .
We previously showed that Korean Red Ginseng (KRG) efficiently blocks hypoxia-induced COX-2 mediated by sirtuin-1 (SIRT-1), the pathway of which differs from that of dexamethasone [28] . This provides scientific evidence of KRG being effective for the suppression of the inflammatory response and tumorigenesis under hypoxia through mechanisms other than those of steroids. We present herein further evidence that KRG suppresses hypoxiainduced COX-2 and is dependent on the PPARg signaling pathway and that PPARg activation by KRG may reduce the tumorigenesis of pulmonary epithelial cells.
Materials and methods

Materials
KRG was kindly supplied by the Korea Ginseng Cooperation (Daejeon, Korea). KRG is prepared from roots of 6-yr-old KRG. Voucher specimen (KGC No. 201-3-1081) of KRG was deposited at the herbarium located at KGC Central Research Institute (Daejeon, Korea). Yield of KRG extract was 75%. The water content of the pooled extract was 36% of total weight. Phytochemical characteristics of KRG with standard ginsenosides were identified by HPLC analysis as reported previously [29, 30] . HPLC analysis result of standard ginsenosides is provided by Korea Ginseng Cooperation [28] . The ginsenoside content in KRG is 7%, and it is composed of major ginsenosides (G-Rg1, 1.79 mg/g; G-Re, 1.86 mg/g; G-Rf, 1.24 mg/g; G-Rh1, 1.01 mg/g; G-Rg2s, 1.24 mg/g; G-Rb1, 7.44 mg/g; G-Rc, 3.04 mg/g; G-Rb2, 2.59 mg/g; and G-Rd, 0.91 mg/g), and other minor ginsenoside components [29, 30] . GW9662 and celecoxib were purchased from Sigma (St. Louis, MO, USA). T0070907 was purchased from Selleckchem (Houston, TX, USA). Fetal bovine serum (FBS), Trizol Reagent, and penicillin/streptomycin were purchased from GIBCO Invitrogen (Grand Island, NY, USA). Anti-COX-2 was obtained from Cayman Chemical (Ann Arbor, MI, USA). Anti-b-actin was purchased from Sigma. Anti-sirtuin-1 (SIRT-1), anti-PPARg and anti-peroxisome proliferator-activated receptor gamma coactivatior-1 alpha (PGC-1a) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell culture and hypoxic conditions
Human pulmonary epithelial A549 cells were maintained in Roswell Park Memorial Institute medium (RPMI) containing 10% FBS and penicillin/streptomycin. Cells were grown at 37 C in a humidified atmosphere of 95% air/5% CO 2 and fed every 2e3 d. Before treatment, the cells were washed with phosphate-buffered saline and cultured in RPMI/5% charcoaledextran stripped FBS (CD-FBS) for 2 d. For the hypoxic condition, cells were incubated at a CO 2 level of 5% with 1% O 2 balanced with N 2 using a hypoxic chamber (Thermo Fisher Scientific, Waltham, MA, USA). KRG stock was prepared at 10 mg/mL in phosphate buffer saline and diluted with media to 1 mg/mL just prior to use and sterilized by filtration with a 0.22 mm bottle top filter (Thermo Fisher Scientific).
Transfection and luciferase assays
A549 cells were transiently transfected with plasmids by using the polyethylenimine (Polysciences, Warrington, PA, USA). Luciferase activity was determined 48 h after treatment with an AutoLumat LB9507 luminometer (EG & G Berthold, Bad Widbad, Germany) using the luciferase assay system (Promega Corp., Madison, WI, USA) and expressed as relative light units. PPARg-responsive element-Luciferase (PPRE-Luc), a firefly luciferase reporter construct containing PPRE-elements, was kindly provided Dr. Ron Evans (The Salk Institute, San Diego CA, USA).
Reverse transcription-polymerase chain reaction
Total RNA was extracted using Trizol Reagent according to the manufacturer's instruction. To synthesize first strand cDNA, 3 mg total RNA was incubated at 70 C for 5 min with 0.5 mg of random hexamer and deionized water (up to 11 mL). 
Western blot analysis
Protein was isolated in lysis buffer (150mM NaCl, 50mM TrisHCl, 5mM EDTA, 1% Nonidet P-40, 0.5% deoxycholate, 1% SDS) with protease inhibitor cocktail (Sigma) on ice for 1 h and then centrifuged for 20 min at 13,000g. Supernatant was collected and protein concentrations were measured using the Bradford method (Bio-Rad, Hercules, CA, USA). Proteins were dissolved in sample buffer and boiled for 5 min prior to loading onto an acrylamide gel. After SDS-PAGE, proteins were transferred to a polyvinylidene difluoride membrane, blocked with 5% nonfat dry milk in Trisbuffered saline containing 0.1% Tween-20 (TBST) for 60 min at room temperature. The membranes were incubated for 2 h at room temperature with antibody. Equal lane loading was assessed using b-actin monoclonal antibody (Sigma). After washing with TBST, blots were incubated with 1:5,000 dilution of the horseradish peroxidase conjugated-secondary antibody (Invitrogen, Grand Island, NY, USA), and washed again three times with TBST. The transferred proteins were visualized with an enhanced chemiluminescence detection kit (GE Healthcare Life Sciences, Pittsburgh, PA, USA).
Cell migration and invasion assays
The migration assay was performed with transwell inserts that have 6.5 mm polycarbonate membranes with 8.0 mm pores (Corning Inc., NY, USA). Matrigel invasion assay was performed using membranes coated with matrigel matrix (BD Science, Sparks, MD, USA). A549 cells were seeded into the upper chamber in serum-free media. The lower chambers consisted of RPMI media containing 10% FBS. After incubation under normoxia or hypoxia for 24e48 h, noninvasive cells present on the upper surface of the membrane were scraped with cotton swabs and the invasive cells present on the lower side of the membrane were fixed with ice cold methanol, stained with 0.1% crystal violet. The cells that migrated and invaded to the lower side of the filter were observed using a light microscope and counted.
Statistical analysis
All data were analyzed and expressed as means and standard deviations. The two-tailed, unpaired Student t test was applied using SPSS software (version 23.0; IBM, Armonk, NY, USA). The t test was used to compare data between the hypoxia and KRGtreated groups. The criterion for statistical significance was p < 0.05.
Results
KRG induces PPARg and inhibits hypoxic induction of COX-2 expression in A549 cells
COX-2 is transcriptionally induced by hypoxia and has been implicated in tumor progression and angiogenesis in tumor cells. We have previously shown that KRG inhibits COX-2 expression under hypoxia in A549 lung cancer cells, where COX-2 is also strongly implicated in tumorigenesis [28] . In the course of studying the mechanism of KRG inhibition of COX-2 under hypoxia, the protein levels of PPARg were examined. A549 cells were preincubated with KRG for 1 h and cotreated with hypoxia. KRG at doses of 500e2,000 mg/mL increased PPARg protein levels. At the same time, as observed previously, KRG efficiently blocked the expression of hypoxia-induced COX-2 protein (Fig. 1A) . KRG at doses of 100e2,000 mg/mL activated PPARg luciferase reporter activity. To confirm that the activities of KRG are PPARg-mediated, we cotreated the cells with the PPARg antagonist T0070907 at a concentration of 5mM, which is enough to block almost all the PPARg on the cells. A known PPARg agonist, rosiglitazone, was used as a positive control. The transcriptional activation of the reporter plasmid by KRG was blocked by T0070907, indicating that luciferase gene activation is PPARg-specific (Fig. 1B) . The concentration of 100e500 mg/mL KRG was chosen as the treatment condition in further experiments because KRG exerted its efficacy with no effect on cell viability at these concentrations (Fig. 1C) .
To further confirm the involvement of PPARg in inhibiting the hypoxic induction of COX-2, COX-2 was examined after treatment with another PPARg antagonist, GW9662. In accordance with our previous report, SIRT-1 levels were increased with KRG treatments. The enhanced protein levels of SIRT-1, PPARg, and COX2 were blocked by GW9662, suggesting that the response involves PPARg ( Fig. 2A) . Induction of COX-2 occurs mostly at the transcription level.
Inhibition of COX-2 at the mRNA level by 500 mg/mL KRG was blocked by GW9662 (Fig. 2B) . These results indicate that the inhibition of hypoxia-induced COX-2 regulation by KRG at the transcription and translation levels in A549 cells is dependent on PPARg. 
KRG inhibits cellular migration and invasion of A549 cells under hypoxia
To determine whether hypoxia induces cell migration via COX2edependent PGE2 production in A549 cells, cell migration was examined with the COX-2 inhibitor, celecoxib. Hypoxia-induced cell migration was inhibited by celecoxib, suggesting that COX-2 plays an important role in hypoxia-induced cell migration (Fig. 3A) . KRG decreased the migration of A549 cells under hypoxic conditions by approximately 50%. KRG inhibition of cell migration was significantly blocked by GW9662 and T0070907, indicating that the effects of KRG on hypoxia-induced migration are mediated by PPARg (Fig. 3B) . Similarly, hypoxia enhanced A549 cell invasion and KRG treatments significantly decreased this effect (Fig. 4) . Inhibition of invasiveness was absent in the presence of GW9662, indicating that the anti-invasive effects of KRG under hypoxic conditions are dependent on PPARg. The invasiveness was absent in the presence of PPARg inhibitors, indicating that the anti-invasive properties of KRG under hypoxic microenvironments require PPARg activation and occur via a COX-2/PGE2-dependent pathway. However, this migration and invasion were also inhibited by SIRT-1 inhibitors [28] , suggesting that this cellular movement is a complicated phenomenon relying on multiple factors.
Discussion
We have recently reported that SIRT-1 is an important player in the suppression of hypoxia-induced COX-2 by KRG in A549 cells [28] . We suggested that SIRT-1 activation by KRG has potential therapeutic value in the suppression of inflammation and in cancer therapies under hypoxic conditions. COX-2 is rapidly induced by various stimuli such as LPS, high osmolarity, and hypoxia, and plays a pivotal role in the production of proinflammatory eicosanoids. High levels of PGE2 synthesized by COX-2 are an important mediator in airway inflammatory responsiveness and angiogenesis involved in tumor development [34] . Many reports have shown that KRG possesses antiinflammatory and antioxidant properties both in vitro and in vivo [35, 36] . However, better understanding of the molecular mechanisms underlying the inhibitory effect of KRG on hypoxia-induced COX-2 is still needed. In this study, we examined the PPARg-mediated KRG inhibition of COX-2 under hypoxia and showed that PPARg activation is responsible for COX-2 suppression under hypoxia.
Peroxisome Proliferator-Activated Receptors (PPARs) is a ligandactivated transcription factor and regulates diverse biological functions including adipocyte differentiation, lipogenesis, inflammation, and insulin sensitivity. PPARg is one pathway that modulates the thriving of cancer cells by multiple complex pathways, thereby sustaining uncontrolled tumor growth. Endogenous ligands including prostaglandins (15d-PGJ2) and synthetic ligands including the antidiabetic thiazolidinediones are known to bind PPAR. Upon ligand binding, PPAR is modified by phosphorylation, sumoylation, ubiquitination, and acetylation. PPARg is acetylated by CBP/p300 and deacetylated by SIRT-1 [37] .
Some PPARg-activating ligands that modulate inflammation have been discovered from natural products such as curcumin, alpha-linolenic acid, magnolol, and orange peel extract [38e41]. A recent report showed that fisetin, a flavonol present in vegetables and fruits, upregulates adiponectin with antiobesity, antidiabetic, and antiatherosclerotic functions through the activation of SIRT-1 and PPAR [42] . Ginsenosides from ginseng showed differential response to PPAR activation. Ginsenosides Re and Rg1 showed inhibitory effects on the differentiation of 3T3-L1 adipocytes [43] . However, ginsenosides Rb2, Rb3, and Rc displayed promotional activities [44] . Ginsenoside-Rg3 induces inhibition of adipogenesis through the activation of AMP-activated protein kinase (AMPK) and the inhibition of PPARg transcriptional activity in 3T3-L1 adipocytes [45] . Protopanaxatriol is a novel PPARg antagonist with moderate binding activity [44] . By contrast, Ginsenoside-Rb1 binds to PPARg, attenuates central inflammation and leptin resistance, reduces the release of free fatty acid, and alleviates the ectopic deposit of triglyceride by upregulating the expression of perilipin in adipose tissue [26] . Ginsenoside-Re reduces insulin resistance through activation of PPARg pathway and inhibited the production of inflammatory cytokine [43] . Ginsenoside-Rg1 can increase the insulin-degrading enzyme expression in the hippocampus by upregulating PPARg, attenuated hippocampal histopathological abnormalities, and improved learning and memory in a rat model of Alzheimer's disease [46] . Our study showed that total ginseng extract exhibited PPARg and SIRT-1 activation with simultaneous suppression of COX-2. Our observation was derived from the sum of activity from each component and interactions between the components. These results will aid our understanding of how ginseng is beneficial in the treatment of metabolic disorders. Our data imply that KRG inhibits COX-2 expression by increasing SIRT-1 deacetylase activity, leading to increased interactions with the PPAR complex and ultimately transcriptional activation. The activation of SIRT-1 by KRG may deacetylate PGC-1a, which in turn may increase its interaction with the PPAR complex to suppress COX-2 transcription. Our ongoing study is designed to characterize the COX-2 suppression and PPARg activation functions of each ginsenoside in A549 cells, as used in this study, and 3T3L1 preadipocytes. Our findings are important for the clinical usage of ginseng and provide a mechanistic explanation of its effects on metabolic disorders and cancer.
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